ThinkCyte
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
ThinkCyte develops AI-driven, label-free cell sorting technology for accelerating drug discovery and cellular therapy development.
OncologyImmunologyRegenerative Medicine
Technology Platform
Ghost Cytometry: A label-free, high-throughput cell analysis and sorting technology that uses structured illumination to capture high-dimensional morphological waveforms, which are classified in real-time by AI.
Opportunities
Significant growth opportunity in providing label-free, AI-enhanced tools for cell therapy manufacturing QC and phenotypic drug discovery, markets that are expanding rapidly.
The cloud-based MorphoScan platform offers a scalable software revenue model.
Risk Factors
Competition from established flow cytometry giants and the challenge of convincing researchers to switch from well-understood, label-based methods to a novel, AI-dependent platform.
Market adoption speed is a key commercial risk.
Competitive Landscape
Competes with traditional flow cytometry companies (BD, Beckman Coulter) and advanced analysis firms (Cytek). Differentiates through unique label-free, high-throughput morphological sorting enabled by proprietary AI and the Ghost Cytometry method.